The poster presentation (Abstract No. 593) "Blue Light Cystoscopy versus White Light Cystoscopy for the Detection of Bladder Cancer in
The study included 158 patients enrolled in an RCT, of which 114 underwent Blue Light Cystoscopy (BLC®) with Hexvix. 19 patients were included in the real-world study (RWS). Among patients diagnosed with Ta, T1, or CIS, 42 out of 97 patients (43.3%) in the RCT and 4 out of 12 patients (33.3%) in the RWS had at least one lesion detected with BLC but not with white light cystoscopy (WLC) (p<0.0001).
Both the RCT and RWS confirmed that Blue Light Cystoscopy with Hexvix demonstrated superior detection of bladder cancer in the Chinese population compared to WLC, especially in the CIS population, with good tolerability.
See Asieris' full release here: https://asieris.com/asieris-releases-phase-iii-clinical-study-and-real-world-research-data-for-apl-1706-a-bladder-cancer-diagnosis-and-management-drug-at-the-2024-asco-gu/
Note to editors:
All trademarks mentioned in this release are protected by law and are registered trademarks of
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer worldwide - the 5th most common in men - with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths in 2020.1b
Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3
Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [January 2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol 2009;27:295-300
4 Bladder Cancer.
About Hexvix®/Cysview® (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.
Cysview is the tradename in the
About
For further information, please contact:
President and CEO
Email: ds@photocure.com
CFO
Tel: +4745055000
Email: ed@photocure.com
Vice President, Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
https://news.cision.com/photocure/r/photocure-partner-asieris-presented-clinical-trial-and-real-world-data-on-hexvix-in-china-at-asco-gu,c3916610
https://mb.cision.com/Main/17498/3916610/2567194.pdf
(c) 2024 Cision. All rights reserved., source